A randomized, double-blind, placebo-controlled phase 2 study of an oral p38α MAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis

被引：0
|
作者：
Genovese, M. C. [1 ]
Cohen, S. B. [2 ]
Wofsy, D. [3 ]
Weinblatt, M. E. [4 ]
Firestein, G. S. [5 ]
Brahn, E. [6 ]
Strand, V. [7 ]
Baker, D. G. [8 ]
Tong, S. E. [9 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Metroplex Clin Res Ctr, Dallas, TX USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Univ Calif San Diego, San Diego, CA 92103 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Stanford Univ, Portola Valley, CA USA
[8] Centocor Inc, Malvern, PA 19355 USA
[9] Scios J&J PRD, Mountain View, CA USA
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S431 / S432
页数：2
相关论文
共 50 条
  • [41] UPADACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF A SELECTIVE JAK1 INHIBITOR
    Genovese, M. C.
    Fleischmann, R.
    Combe, B.
    Hall, S.
    Zhang, Y.
    Zhou, Y.
    Mohamed, M. F.
    Meerwein, S.
    Pangan, A. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 970 - 970
  • [42] SARILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY
    Huizinga, T. W.
    Kivitz, A. J.
    Rell-Bakalarska, M.
    Fleischmann, R. M.
    Jasson, M.
    Radin, A. R.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 60 - 60
  • [43] Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study
    Genovese, Mark C.
    Kivitz, Alan J.
    Simon Campos, J. Abraham
    Rell-Bakalarska, Maria
    Fleischmann, Roy M.
    Jasson, Martine
    Radin, Allen R.
    Huang, Xiaohong
    Huizinga, Tom W. J.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 4041 - 4042
  • [44] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study
    Papp, K
    Mease, P
    Garovoy, M
    Zhang, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [45] Das28 responses in patients with active rheumatoid arthritis who received golimumab and methotrexate: A randomized, double-blind, placebo-controlled phase 2 trial
    Kay, J.
    Matteson, E. L.
    Dasgupta, B.
    Nash, P.
    Durezs, P.
    Hall, S.
    Han, J.
    Rahman, M. U.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 323 - 323
  • [46] Modulation of CCR2 in rheumatoid arthritis - A double-blind, randomized, placebo-controlled clinical trial
    Vergunst, Clarissa E.
    Gerlag, Danielle M.
    Lopatinskaya, Luba
    Klareskog, L.
    Smith, M. D.
    van den Bosch, F.
    Dinant, Huib J.
    Lee, Yih
    Wyant, Timothy
    Jacobson, Eric W.
    Baeten, Dominique
    Tak, Paul P.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (07): : 1931 - 1939
  • [47] Treatment of early rheumatoid arthritis with minocycline or placebo - Results of a randomized, double-blind, placebo-controlled trial
    ODell, JR
    Haire, CE
    Palmer, W
    Drymalski, W
    Wees, S
    Blakely, K
    Churchill, M
    Eckhoff, PJ
    Weaver, A
    Doud, D
    Erikson, N
    Dietz, F
    Olson, R
    Maloley, P
    Klassen, LW
    Moore, GF
    ARTHRITIS AND RHEUMATISM, 1997, 40 (05): : 842 - 848
  • [48] Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
    Genovese, Mark C.
    Spindler, Alberto
    Sagawa, Akira
    Park, Won
    Dudek, Anna
    Kivitz, Alan
    Chao, Jeannie
    Chan, Lai Shan Melanie
    Witcher, Jennifer
    Barchuk, William
    Nirula, Ajay
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 969 - 976
  • [49] Treatment of patients with undifferentiated arthritis with methotresate: a double-blind, placebo-controlled, randomized
    van Dongen, H
    van Aken, J
    Lard, LR
    Ronday, HK
    Speyer, I
    Westedt, ML
    Allaart, CF
    Breedveld, FC
    Huizinga, TW
    ARTHRITIS AND RHEUMATISM, 2005, 52 (12): : 4058 - 4059
  • [50] A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
    Fleischmann, Roy M.
    Damjanov, Nemanja S.
    Kivitz, Alan J.
    Legedza, Anna
    Hoock, Thomas
    Kinnman, Nils
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (02) : 334 - 343
12345